Allogene Therapeutics, Inc. revenue for the last year amounted to 95.00 k USD, the most of which — 95.00 k USD — came from its highest performing source at the moment, Allogeneic T Cell Therapies, the year earlier bringing 243.00 k USD. The greatest contribution to the revenue figure was made by United States — last year it brought Allogene Therapeutics, Inc. 95.00 k USD, and the year before that — 243.00 k USD.